Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report) shares fell 8.8% during mid-day trading on Tuesday . The company traded as low as $1.55 and last traded at $1.55. 135 shares were traded during trading, a decline of 94% from the average daily volume of 2,171 shares. The stock had previously closed at $1.70.
Mesoblast Price Performance
The firm has a 50 day simple moving average of $1.65 and a 200 day simple moving average of $1.63.
About Mesoblast
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
Recommended Stories
- Five stocks we like better than Mesoblast
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
